Specific allergy immunotherapy traditionally has been thought of as subcutaneous injection immunotherapy (SCIT). There also are noninjection routes for the administration of immunotherapy. The best-known and studied of these noninjection routes is the sublingual route, usually known as sublingual immunotherapy (SLIT). SLIT has been in use for many decades; however, to this date, it is not well known to the majority of allergy practitioners in this country. The purpose of this study is to help change this perception so that SLIT eventually can be considered one more tool in the allergist's armamentarium.
Methods
A literature review was performed. It included articles from the early American clinicians and present publications that are mostly of European origin.
Results
It will become clear to the reader that the key features of SLIT are its efficacy, great safety, and simplicity of administration.
Conclusion
SLIT is a safe treatment modality that should be considered as a useful additional tool in the therapeutic armamentarium.
CurtisH.H.The immunizing cure of hay fever.Med News, New York77: 16, 1900.
2.
CanonicaG.W., and PassalacquaG.Non Injections routes for immunotherapy.J Allergy Clin Immunol111: 437–448, 2003.
3.
BouquetJ.The new ARIA guidelines: Putting science into practice.Clin Exp Allergy Rev2: 38–43, 2002.
4.
BousquetJ., and the ARIA Workshop Group. Allergic rhinitis and its impact on asthma.J Allergy Clin Immunol108(suppl 5): 242–245, 2001.
5.
KagiM.K., and WuthrichB.Different methods of local allergen-specific immunotherapy. Review article.Allergy57: 379–388, 2002.
6.
BellantiJ.A., and SettipaneR.A.Sublingual immunotherapy: A procedure whose time has come?Asthma Allergy Proc28: 1–2, 2007.
7.
HanselF.K.Treatment of hay fever. In Allergy of the Nose and Paranasal Sinuses.St. Louis: CV Mosby, 755, 1936.
8.
VaughanW.T., and BlackJ.H. (Eds.). Pollens and pollinosis, other inhalant allergy.In Practice of Allergy, 3rd ed.St. Louis: CV Mosby Co., 697–698, 1954.
9.
RuddyL.W.Why sublingual therapy in otolaryngologic allergy?Trans Am Soc Oph Otol All17: 93–102, 1976.
10.
DickeyL.W.Sublingual antigen testing and therapy for inhalants, foods and petrochemicals, In Clinical Ecology.DickeyL. (Ed). Springfield, IL: Charles C. Thomas Publisher, 544–553, 1976.
11.
HanselF.K.Sublingual testing and therapy. A comparison with injectable methods.Trans Am Soc Ophtalmol Otolaryngol Allergy11: 93–103, 1972.
12.
Kleine-TebbeJ., RibelM., and HeroldD.A.Safety of a SQ-standardized grass allergen tablet for sublingual immunotherapy: A randomized, placebo-controlled trial.Allergy61: 181–184, 2006.
13.
AndreC., VatrinetC., GalvainS.Safety of sublingual-swallow immunotherapy in children and adults.Int Arch Allergy Immunol121: 220–234, 2000.
14.
Van DeusenM.A., AngeliniB.L., CordoroK.M.Efficacy and safety of oral immunotherapy with short ragweed extract.Ann Allergy Asthma Immunol78: 573–579, 1997.
15.
Di RienzoV., MarcucciF., PuccinelliP.Long-lasting effect of immunotherapy in children with asthma due to house dust mite: A 10-year prospective study.Clin Exp Allergy33: 206–210, 2003.
LeathermanB.D., OwenS., ParkerM.Sublingual immunotherapy: Past, present, paradigm for the future? A review of the literature.Otolaryngol Head Neck Surg136: S1–S20, 2007.
WilsonD.R., Torres LimaR., and DurhamS.R.Sublingual immunotherapy for allergic rhinitis: Systematic review and meta-analysis.Allergy60: 4–12, 2005.
20.
BagnascoM., PassalacquaG., VillaG.Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy is allergic volunteers.Clin Exp Allergy31: 54–60, 2001.
21.
MorrisD.L.Current use of sublingual-swallow immunotherapy.Curr Opin Otolaryngol Head Neck Surg9: 179–180, 2001.
22.
BrownJ.L., and FrewA.J.The efficacy of oro-mucosal immunotherapy in respiratory allergy.Clin Exp Allergy31: 8–10, 2001.
23.
BousquetJ.Sublingual immunotherapy: From proven to putative rapid relief of allergic symptoms.Allergy60: 1–3, 2005.
24.
AkdisM., Scmidt-WeberC., JutelM.Mechanisms of allergen immunotherapy.J World Allergy Org16: 65–69, 2004.
25.
CiprandiG., FenoglioD., CirilloI.Sublingual immunotherapy: An update on immunologic and functional effects.Allergy Asthma Proc28: 40–43, 2007.
26.
Della VolpeA., D'AgostinoG.W., VarricchioA.M., and MansiN.Sublingual allergen-specific immunotherapy in allergic rhinitis and related pathologies: Efficacy in a paediatric population.Int J Immunopathol15: 35–40, 2002.
27.
PajnoG.B., MorabitoL., and ParmianiS.Clinical and immunological effects of long term immunotherapy in asthmatic children sensitized to mites: A double-blind placebo-controlled study.Allergy55: 842–849, 2000.
28.
HirschTh, SahnM., and LeupoldW.Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children.Pediatr Allergy Immunol8: 21–27, 1997.
29.
SaportaD., and McDanielA.B.Safety and efficacy comparison of multiple-antigen subcutaneous immunotherapy with multiple-antigen sublingual Immunotherapy.ENT J86: 493–497, 2007.
BakerS.P.The use of sublingual drop therapy in allergy. In Clinical Ecology.DickeyL. (Ed). Springfield, IL: Charles C. Thomas Publisher, 554–555, 1976.
32.
MadoniniE., AgostinisF., BarraR.Safety and efficacy evaluation of sublingual allergen-specific immunotherapy. A restrospective multicenter study.Int J Immunopathol Pharmacol13: 27–81, 2000.
33.
GrosclaudeM., BouillotP., AltR.Safety of various dosage regimens during Induction of sublingual immunotherapy.Int Arch Allergy Immunol129: 248–253, 2002.
34.
FelizianiV., LattuadaG., ParmianiS., and Dall’ AglioP.P.Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study.Allergol Immunopathol23: 224–230, 1995.
35.
SamburgoR., PuccinelliP., BurasteroS.E., and Di RienzoV.The efficacy of sublingual immunotherapy for respiratory allergy is not affected by different dosage regimens in the induction phase.Allergol Immunopathol31: 329–337, 2003.
36.
PotterP.C.Update on sublingual immunotherapy.Ann Allergy Asthma Immunol96: S22–S25, 2006.
37.
DurhamS.R., WalkerS.M., VargaE.M.Long term clinical efficacy of grass pollen immunotherapy.N Eng J Med341: 468–475, 1999.
38.
JacobsenL., Nuchel PetersenB., WihlJ.A.Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up.Allergy52: 914–920, 1997.
39.
BousquetJ., ScheinmannP., GuinnepainM.T.Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: A double-blind, placebo-controlled study.Allergy54: 249–260, 1999.
40.
ClavelR., BousquetJ., and AndreC.Clinical efficacy of sublingual-swallow immunotherapy: A double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis.Allergy53: 493–498, 1998.
41.
HurstD.S., GordonB.R., FornadleyJ.A., and HunsakerD.H.Safety of home based and office allergy immunotherapy: A multicenter prospective study.Otol Head Neck Surg121: 553–561, 1999.
42.
LiJ.T., LockeyR.F., BernsteinL.Allergen immunotherapy: A practice parameter.Ann Allergy Asthma Immunol90: 1–40, 2003.
43.
PfeifferG.O.Sublingual diagnosis and treatment.Trans Am Soc Ophtalmol Otolaryngol Allergy15: 109–113, 1975.
44.
DunskyE.H., GoldsteinM.F., DvarinD.J., and BelecanechG.A.Anaphylaxis to sublingual immunotherapy.Allergy61: 1235, 2006.
45.
AnticoA., PaganiM., and CremaA.Anaphylaxis by latex immunotherapy.Allergy61: 1236–1237, 2006.
46.
NelsonH.S.Allergen immunotherapy: Where is it now?J Allergy Clin Immunol119: 769–777, 2007.
47.
FinegoldI.Allergen immunotherapy: Present and future.Allergy Asthma Proc28: 44–49, 2007.
48.
RuddyL.W.Why sublingual therapy in otolaryngologic allergy.Trans Am Soc Ophtalmol Otolaryngol Allergy17: 93–102, 1976.
49.
LombardiC., GaniF., LandiM.Quantitative assessment of the adherence to sublingual immunotherapy.J Allergy Clin Immunol113: 1219–1220, 2004.
50.
BousquetJ., DemolyP., and MichelF.B.Specific immunotherapy in rhinitis and asthma.Ann Allergy Asthma Immunol87: 38–42, 2001.
51.
BramanS.S., BarrowsA.A., DeCotiisB.A.Airway hyper-responsiveness in allergic rhinitis. A risk factor for asthma.Chest91: 671–674, 1997.
52.
CookP.R., BryantJ.L., DavisW.E.Systemic reactions to immunotherapy: The American Academy of Otolaryngic Allergy Morbidity and Mortality Survey.Otolaryngol Head Neck Surg110: 487–493, 1994.
53.
LinnaO., KokkonenJ., and LukinM.A 10 year prognosis for childhood allergic rhinitis.Acta Paediatr81: 100–102, 1992.
54.
MollerC., DreborgS., FerdousiH.A.Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study).J Allergy Clin Immunol109: 251–256, 2002.
55.
Des RochesA., ParadisL., MenardoJ.L.Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.J Allergy Clin Immunol99: 450–453, 1997.
56.
FornadleyJ.A., CoreyJ.P., OsguthorpeJ.D.Allergic rhinitis: Clinical practice guideline.Otolaryngol Head Neck Surg115: 115–122, 1996.
57.
GordonB.R., and VelingM.C.Safety of beta blockade during intradermal dilution testing, quantitative testing, or immunotherapy. Presented at the American Academy of Otolaryngic Allergy Annual Meeting, Toronto, CA, September 15, 2006.
58.
CanonicaG.W., Baena-CagnaniC.E., BousquetJ.Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO).Allergy62: 317–324, 2007.
59.
RoderE., BergerM., HopW.Sublingual immunotherapy is not effective in symptomatic youngsters in primary care.J Allergy Clin Immunol119: 892–898, 2007.
